KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

AbbVie (ABBV) Research & Development (2016 - 2025)

Historic Research & Development for AbbVie (ABBV) over the last 14 years, with Q3 2025 value amounting to $2.3 billion.

  • AbbVie's Research & Development rose 887.32% to $2.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $13.3 billion, marking a year-over-year increase of 6730.87%. This contributed to the annual value of $12.8 billion for FY2024, which is 6665.8% up from last year.
  • AbbVie's Research & Development amounted to $2.3 billion in Q3 2025, which was up 887.32% from $2.1 billion recorded in Q2 2025.
  • AbbVie's Research & Development's 5-year high stood at $6.8 billion during Q4 2024, with a 5-year trough of $1.5 billion in Q1 2022.
  • For the 5-year period, AbbVie's Research & Development averaged around $2.1 billion, with its median value being $1.8 billion (2021).
  • Over the last 5 years, AbbVie's Research & Development had its largest YoY gain of 25153.09% in 2024, and its largest YoY loss of 1540.14% in 2024.
  • Over the past 5 years, AbbVie's Research & Development (Quarter) stood at $1.8 billion in 2021, then fell by 2.03% to $1.8 billion in 2022, then rose by 7.65% to $1.9 billion in 2023, then soared by 251.53% to $6.8 billion in 2024, then plummeted by 65.77% to $2.3 billion in 2025.
  • Its Research & Development stands at $2.3 billion for Q3 2025, versus $2.1 billion for Q2 2025 and $2.1 billion for Q1 2025.